SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023.
“We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the quarter to provide us with additional operating runway,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio.
Highlights
Strengthened balance sheet and board of directors:
Successful on-time launch of three BioXp® kits:
Delivered operational milestones, including:
The company’s expectation is that these insourcing efforts will be substantially completed by year-end and that full financial benefit will be realized in 2024.
Second Quarter 2023 Financial Results
Revenue was $8.7 million for the second quarter 2023, a 53% increase from $5.7 million for the same period in the prior year. This growth was primarily driven by achievement of another collaboration milestone and sales of BioXp systems.
Gross margins were 65.8% for the second quarter compared to 48% for the same period in the prior year, driven by the completion of a milestone under our agreement with Pfizer and reflecting a positive mix shift in revenue from recently launched products within our growing BioXp portfolio.
Operating expenses were approximately $13.7 million for the second quarter 2023 compared to $17.2 million for the same period in the prior year. This decrease is primarily a result of ongoing cost-cutting decisions including a reduction in force during the quarter to focus the team on our most profitable and near-term opportunities. This is the fourth consecutive quarter the company has successfully reduced or maintained its operating expenses while growing revenue on a year-over-year basis.
Net loss was $8.3 million for the second quarter 2023, compared to a loss of $14.8 million in the same period in the prior year. Net loss per share was $0.28 for the second quarter of 2023, compared to $0.50 for the corresponding prior year period.
Cash, cash equivalents, and investments were $47.5 million as of June 30, 2023.
Webcast and Conference Call Information
Company management will host a conference call today, Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of Telesis Bio’s website at ir.telesisbio.com and the conference call can be accessed live by pre-registering here: https://register.vevent.com/register/BI5027491b111b49a6a5d05999b6cf5bb6. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on our website for 30 days.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Contact:
Jen Carroll
Vice President of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Telesis Bio Inc.
Selected Statements of Operations Financial Data
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue: | |||||||||||||||
| Product sales | $ | 2,670 | $ | 2,337 | $ | 5,671 | $ | 4,760 | |||||||
| Service revenue | 1,713 | 1,755 | 3,387 | 3,460 | |||||||||||
| Collaboration revenue | 3,462 | 962 | 4,424 | 1,924 | |||||||||||
| Royalties and other revenue | 807 | 601 | 1,486 | 1,147 | |||||||||||
| Total revenue | 8,652 | 5,655 | 14,968 | 11,291 | |||||||||||
| Cost of revenue | 2,959 | 2,943 | 5,764 | 5,801 | |||||||||||
| Gross Profit | 5,693 | 2,712 | 9,204 | 5,490 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 4,587 | 6,950 | 9,708 | 13,255 | |||||||||||
| Sales and marketing | 3,360 | 4,688 | 7,167 | 8,225 | |||||||||||
| General and administrative | 5,712 | 5,561 | 11,266 | 11,360 | |||||||||||
| Total operating expenses | 13,659 | 17,199 | 28,141 | 32,840 | |||||||||||
| Loss from operations | (7,966 | ) | (14,487 | ) | (18,937 | ) | (27,350 | ) | |||||||
| Interest expense, net | (333 | ) | (299 | ) | (582 | ) | (635 | ) | |||||||
| Change in fair value of derivative liabilities | 19 | (27 | ) | 159 | (4 | ) | |||||||||
| Other expense, net | (3 | ) | (12 | ) | (39 | ) | (24 | ) | |||||||
| Provision for income taxes | (4 | ) | (6 | ) | (7 | ) | (12 | ) | |||||||
| Net loss | $ | (8,287 | ) | $ | (14,831 | ) | $ | (19,406 | ) | $ | (28,025 | ) | |||
| Less: redeemable convertible preferred stock dividends | (153 | ) | — | (153 | ) | — | |||||||||
| Net loss attributable to common stockholders | $ | (8,440 | ) | $ | (14,831 | ) | $ | (19,559 | ) | $ | (28,025 | ) | |||
| Net loss per share, basic and diluted | $ | (0.28 | ) | $ | (0.50 | ) | $ | (0.66 | ) | $ | (0.95 | ) | |||
| Weighted average common stock outstanding—basic and diluted | 29,774,275 | 29,435,838 | 29,718,948 | 29,383,870 | |||||||||||
Telesis Bio Inc.
Selected Balance Sheet Financial Data
(in thousands)
(unaudited)
| June 30, | December 31, | ||||||
| 2023 | 2022 | ||||||
| Balance Sheet Data: | |||||||
| Cash, restricted cash, cash equivalents and short-term investments | $ | 47,530 | $ | 43,753 | |||
| Working capital | 51,157 | 41,594 | |||||
| Total assets | 114,526 | 81,362 | |||||
| Total liabilities | 58,457 | 34,797 | |||||
| Redeemable convertible preferred stock | 28,153 | — | |||||
| Accumulated deficit | (133,147 | ) | (113,741 | ) | |||
| Total stockholders’ equity | 27,916 | 46,565 | |||||
| Last Trade: | US$0.45 |
| Daily Change: | -0.15 -25.00 |
| Daily Volume: | 2,300 |
| Market Cap: | US$801K |
September 25, 2024 November 13, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
